一个由2，4-吡啶二甲酸和1，4-双(咪唑基-1-甲基)苯构筑的钴配位聚合物的水热合成和晶体结构

通过水热法合成了一个金属-有机配位聚合物[Co(PDC)(bix)(H2O)]n(H2PDC=2,4-吡啶二甲酸,bix=1,4-双(咪唑基-1-甲基)苯)。并对其进行了元素分析、热重、红外光谱、紫外光谱和X-射线单晶衍射测定。该配合物属于单斜晶系,C2/c空间群。晶体学数据:a=2.5255(4),b=1.31898(19),c=1.4415(2)nm,β=118.656(2)°,V=4.213 5(11)nm3,C21H19CoN5O5,Mr=480.34,Dc=1.514 g.cm-3,μ(Mo Kα)=0.857 9 mm-1,F(000)=1 976,Z=8,残差因子R=0.030 5,wR=0.067 4。在晶体结构中,钴原子为六配位与来自2个不同的PDC配体上的2个羧基氧原子和来自2个bix配体上的2个氮原子、来自PDC配体上的1个氮原子以及1个配位水分子配位,呈现畸变的八面体几何构型。而且该配合物通过氢键作用扩展成三维超分子网状结构。     

3-(2,4-二羧基苯基)-2,6-二羧基吡啶原位脱羧构筑两个配位聚合物的结构及磁性

通过水热法合成了2个配位聚合物:[Cu(H2dpcp)2]n(1)和[Mn2(Hdpcp)2(H2O)2·2H2O]n(2)[H3dpcp=5-(2,4-二羧基苯基)-2-羧基吡啶],H3dpcp由3-(2,4-二羧基苯基)-2,6-二羧基吡啶(H4dpdp)原位脱羧生成。X-射线单晶衍射测得2个化合物都属于单斜晶系,化合物1结晶在P21/c空间群,a=0.639(13)nm,b=1.835(4)nm,c=1.115(2)nm,β=102.29(3)°,Z=2;化合物2结晶在C2/c空间群,a=3.126(6)nm,b=1.004(2)nm,c=1.080(2)nm,β=93.73(3)°,Z=4。化合物1以配体H2dpcp-桥连Cu( Ⅱ)形成一维链状结构。化合物2通过Hdpcp2-桥连Mn( Ⅱ)形成二维层状结构,并进一步通过氢键作用形成三维超分子结构。负的Weiss常数θ表明化合物2存在反铁磁耦合作用。     

三维Y(Ⅲ)-Ag(Ⅰ)异金属配位聚合物的合成、晶体结构与性质研究

以异烟酸(Hina)和2-磺基苯甲酸(H2L)为配体,在水热条件下与Y(Ⅲ)和Ag(Ⅰ)离子进行协同配位,合成了一个异金属配位聚合物[Y2Ag2L2(ina)4(H2O)2]n(1)。通过X-射线衍射、热重分析、元素分析和红外光谱对其进行表征。X-射线单晶衍射测定其结构为单斜晶系,P21/n空间群,晶胞参数a=0.914 43(3)nm,b=1.378 39(5)nm,c=1.760 76(5)nm,β=102.315(3)°,V=2.168 27(12)nm3,Z=4。它含有一个以羧基O原子桥连的中心对称的四核异金属原子簇[Y2Ag2L2],相邻的原子簇之间通过异烟酸配体相互连接成三维金属有机骨架结构。     

以4-[(羧甲基)硫代]-苯甲酸为配体的Pb(Ⅱ)和Cd(Ⅱ)配位聚合物的合成、结构以及荧光性质

在混合溶剂热条件下,以4-[(羧甲基)硫代]-苯甲酸(CMTB)为配体合成了[Pb(CMTB)H2O]n(1)和[Cd(CMTB)]n(2)两个配位聚合物,并用X-射线单晶结构分析、电感耦合等离子光谱和红外光谱对其进行了表征。化合物1属于三斜晶系,空间群为P1,晶胞参数为a=0.645 08(13)nm,b=0.847 83(17)nm,c=0.956 30(19)nm,α=90.37(3)°,β=92.75(3)°,γ=106.40(3)°,Z=2;化合物1具有二维层状结构,每1个Pb(Ⅱ)与来自4个配体的5个氧原子以及1个来自水分子的氧原子配位,形成了1个变形八面体的几何构型。化合物2为单斜晶系,空间群是P21,晶胞参数为a=0.786 27(16)nm,b=0.600 55(12)nm,c=1.001 3(2)nm,β=91.14(3)°,Z=2。化合物2是一个二维层状化合物,Cd(Ⅱ)与5个氧原子和1个硫原子配位形成了六配位的八面体构型。同时,我们对两个配合物的荧光性质进行了研究。     

具有三维网络的新型配位聚合物[Nd(C7H6NO2)32·H2O]n 的合成、结构和性质

以Nd(NO3)3@6H2O和NH2C6H4COOH为原料,经[Nd(C7N6O2)3@H2O]的自组装,得到了具有三维网络结构的配位聚合物[Nd(C7H6NO2)3@H2O]n.该聚合物晶体属单斜晶系,空间群P2(1)/n,a=0.98069(5)nm,b=2.2736(2)nm,c=0.98254(8)nm,β=100.053(5)°,V=2.1571(3)nm3,Z=4.最后的一致性因子R=0.038.磁性研究表明,该化合物在低温下表现出反铁磁性质.测定了化合物的UV-vis-NIR和IR光谱,并进行了分析和指认.     

基于2,5-二甲基苯-1,4-二亚甲基二膦酸的钴、镍同构化合物的水热合成及晶体结构(英文)

在水热条件下,利用2,5-二甲基苯-1,4-二亚甲基二膦酸(H4L)与CoCl2·6H2O或NiSO4·6H2O反应得到2个同构的过渡金属有机膦酸化合物,[Co(H2O)4(H2L)]n(1),[Ni(H2O)4(H2L)]n(2),并用元素分析、红外光谱、粉末及单晶X-射线等方法对其进行了表征。晶体结构分析表明:化合物1和2都属于三斜晶系,空间群为P1,化合物1的晶胞参数为a=0.497 0(2)nm,b=0.711 3(3)nm,c=1.177 8(5)nm,α=97.779(7)°,β=92.103(7)°,γ=107.217(6)°,V=0.3927(3)nm3,Z=2;化合物2的晶胞参数为a=0.494 35(19)nm,b=0.708 9(3)nm,c=1.172 6(5)nm,α=97.919(6)°,β=92.130(6)°,γ=107.441(5)°,V=0.387 0(3)nm3,Z=2。金属离子采取了八面体构型,6个配位氧原子分别来自2个反式构型的H2L配体和4个配位水分子。每1个金属离子与2个反式构型的H2L配体配位形成了一维线型链状结构。这2个化合物最终通过O-H…O氢键作用形成了三维结构。此外,对2个化合物的热稳定性也进行了研究。     

铀-钾异核配位聚合物的合成及晶体结构

在水热反应条件下合成了1种新颖的U(Ⅵ)-K异核配位聚合物[UO2K2(pdc)2(H2O)3]n(H2pdc=吡啶-2,6-二羧酸),通过元素分析、红外、紫外光谱及热重对该配合物进行了表征。单晶结构表明:配合物属于单斜晶系,C2/c空间群;晶胞参数分别为a=1.888 5(6)nm,b=1.490 0(5)nm,c=0.740 2(2)nm,β=111.104(10)°。中心铀及钾原子通过2个氮原子和6个氧原子与吡啶-2,6-二羧酸配体结合。不同的[UO2K2(pdc)2].3H2O单元通过氧原子桥联组成三维链状配位聚合物。配位聚合物中存在π…π相互作用及氢键作用。     

新型二维杂金属配位聚合物[La(Hida)Co(ida)2]·0.5H2O的水热合成与表征

采用水热法合成出一种新型二维杂金属配位聚合物[La(Hida)Co(ida)2].0.5H2O(ida=氨基二乙酸),并通过X射线单晶结构分析、红外光谱分析、元素分析、热重分析以及X射线粉末衍射分析对该化合物进行了表征.结构分析数据表明,该化合物属单斜晶系,C2/c空间群,晶胞参数a=0.97078(19)nm,b=2.4128(5)nm,c=0.85964(17)nm,β=114.91(3),°V=1.8263(6)nm3,Z=4,R=0.0126.该化合物是由一维La-Co杂金属链通过四齿羧酸配体连接形成的新型二维杂金属配位聚合物.     

一维配位聚合物[Ni3(H2btec)1.5(OH)3(2,2''''-bipy)3]n的水热合成及晶体结构

采用水热法合成了一维配位聚合物[N i3(H2btec)1.5(OH)3(2,2-’b ipy)3]n。对其进行了元素分析、红外光谱和X射线单晶衍射测定。该配合物属于单斜晶系,空间群P2(1)/c,晶胞参数a=10.9214(12),b=18.012(2),c=20.566(2),β=94.933(2),°z=4,V=4030.6(8)3,D c=1.765g/cm3,F(000)=2184,R1=0.0483,wR2=0.0972。     

基于环己二酸和双苯并咪唑配体的一维钴(Ⅱ)配位聚合物的合成、结构和催化性能研究

水热条件下,合成了钴(Ⅱ)配位聚合物{[Co(L)(chdc)].2H2O}n(1)(L=1,3-二(苯并咪唑-1-甲基)苯,H2chdc=1,4-环己烷二酸)。结构分析表明,配合物1的晶体属于单斜晶系,C2/c空间群,晶胞参数为a=1.4504(1)nm,b=1.834 9(2)nm,c=2.128 7(2)nm,β=94.325(1)°,V=5.649 2(9)nm3,Z=4。该配合物为一维环状链结构,并进一步通过链间的π-π作用自组装成二维超分子结构。配合物1作为类芬顿反应的催化剂降解刚果红显示较高的活性。     

Syntheses of 1-, 2-, 3- and 4-acridinecarbaldehydes

The four acridinecarbaldehydes, namely, acridine-1-carbaldehyde, acridine-2-carbaldehyde, acridine-3-carbaldehyde, and acridine-4-carbaldehyde have been synthesized for the first time.     

Trifluoromethylthiolation of 1, 3- and 1, 4-Cyclohexadienes

Treatment of 1, 3-cyclohexadiene with CF 3 SCl at m 80°; furnishes 15 compounds. All but the two dimerized adducts arise from the free radical catalyzed addition of CF 3 S and Cl radicals to carbon-carbon double bonds. One dimerized product arises via dimerization of the substrate itself, while the other results from the cross-coupling of the substrate with the reaction product. The same reaction with 1, 4-cyclohexadiene gives 14 compounds. The mass spectral characterization of various compounds and their probable mechanism of formation are presented in this article.     

Derivatives of 2-(3'-coumarinyl)-1, 3-indandione

The possibility of the direct preparation of 2-(3'-coumarinyl)-1,3-indandione and its derivatives by condensing phthalic and substituted phthalic anhydrides with 3-coumarinylacetic acid in acetic anhydride solution in the presence of triethylamine has been shown. The bromination and hydroxymethylation of 2-(3'coumarinyl)-1,3-indandione and its substituted derivatives have been performed.     

5-(1-Alkenyl)-1, 3, 4-oxadiazol-2(3H)-one

3-(2-alkenoyl)-thiocarbazic acid O-methyl esters 1 are desulfurated by bromine and the unknown intermediates are transformed by alkali to 5-(1-alkenyl)-1, 3, 4-oxadiazol-2(3H)-ones ( 2 ). This type of oxadiazolone substitution is not realizable by the common ring closure of hydrazides with phosgene due to pyrazolidinone ring closure of unsaturated acids with hydrazine.     

Asymmetric synthesis of (1R,2S,3R)-3-methylcispentacin and (1S,2S,3R)-3-methyltranspentacin by kinetic resolution of tert-butyl (+/-)-3-methylcyclopentene-1-carboxylate

Conjugate addition of lithium dibenzylamide to tert-butyl (+/-)-3-methylcyclopentene-1-carboxylate occurs with high levels of stereocontrol, with preferential addition of lithium dibenzylamide to the face of the cyclic alpha,beta-unsaturated acceptor anti- to the 3-methyl substituent. High levels of enantiorecognition are observed between tert-butyl (+/-)-3-methylcyclopentene-1-carboxylate and an excess of lithium (+/-)-N-benzyl-N-alpha-methylbenzylamide (10 eq.) (E > 140) in their mutual kinetic resolution, while the kinetic resolution of tert-butyl (+/-)-3-methylcyclopentene-1-carboxylate with lithium (S)-N-benzyl-N-alpha-methylbenzylamide proceeds to give, at 51% conversion, tert-butyl (1R,2S,3R,alphaS)-3-methyl-2-N-benzyl-N-alpha-methylbenzylaminocyclopentane-1-carboxylate consistent with E > 130, and in 39% yield and 99 +/- 0.5% de after purification. Subsequent deprotection by hydrogenolysis and ester hydrolysis gives (1R,2S,3R)-3-methylcispentacin in > 98% de and 98 +/- 1% ee. Selective epimerisation of tert-butyl (1R,2S,3R,alphaS)-3-methyl-2-N-benzyl-N-alpha-methylbenzylaminocyclopentane-1-carboxylate by treatment with KO'Bu in 'BuOH gives tert-butyl (1S,2S,3R,alphaS)-3-methyl-2-N-benzyl-N-alpha-methylbenzylaminocyclopentane-1-carboxylate in quantitative yield and in > 98% de, with subsequent deprotection by hydrogenolysis and ester hydrolysis giving (1S,2S,3R)-3-methyltranspentacin hydrochloride in > 98% de and 97 +/- 1% ee.     

Synthesis of C-Nucleoside Analogues： 2-[2-（Hydroxymethyl）-1, 3-dioxolan-5-yl]1, 3-thiazole-4-carboxamide and 2-[2-（Mercaptometh-yl）-1, 3-dioxolan-5-yl] 1, 3-thiazole-4-carboxamide

Novel C-nucleosides of tiazofurin analogue (2-[2-(hydroxymethyl)-1,3-dioxolan-5-yl] 1,3-thiazole-4-carboxamide) and its thiol-substituted derivative (2-[2-(mercaptomethyl)-1,3-dioxolan-5-yl] 1, 3-thiazole-4-carboxamide) were synthesized from methyl acrylate through a multistep procedure. Their structures were confirmed by IR, ^1HNMR, ^13CNMR and elemental analysis.     

2-芳氧基-5-苯基-1,3,4-噁二唑类化合物的合成

本文通过芳氧基负离子在2—甲磺酰基—苯基—1,3,4—噁二唑环2—位上的亲核取代反应制得9个新的2—芳氧基—5—苯基—l,3,4—噁二唑衍生物。所有化合物的结构经元素分析,IR,~1H NMR和MS确认。初步抗菌实验表明这些化合物具有一定的抑制枯草芽孢杆菌繁殖的活性。 2,5—二取代l,3,4—噁二唑衍生物具有广泛的生物活性,如抗菌,抗黄球菌,除草杀棉花牙虫等。Madhavan等曾通过芳胺在2— 甲磺酰基—5—芳基1,3,4—噁二唑环上的亲核取代反应,制得了2—芳氨基—5—芳基—l,3,4—噁二唑衍生物,我们也曾通过酰肼等亲核试剂在2—甲磺酰基—5—(3,4,5—三甲氧基苯基)—1,3,4—噁二唑环上的亲核取代反应,得到了2—取代酰肼基—5—(3,4,5—三甲氧基苯基)—l,3,4—噁二唑衍生物。在此基础上,我们拟通过Aro在2—甲磺酰基